on 28 Aug 2018
Last Applicant/ Owned by
345 East 94th St., Suite 18A
New York
NY
10128
Serial Number
87555042 filed on 03rd Aug 2017
Registration Number
5548645 registered on 28th Aug 2018
Correspondent Address
Harris A. Wolin
Filing Basis
1. filed as use application
2. use application currently
Disclaimer
NO DATA
drug development services; development of pharmaceutical preparations for the targeted treatment of diseased sites related to cancer, central nervous system and neurological degenerative diseases, neurodevelopmental and psychiatric disorders, and pharmaceutical preparations for the treatment of cancer, central nervous system and neurological degenerative diseases, neurodevelopmental and psychiatri Read More
drug development services; development of pharmaceutical preparations for the targeted treatment of diseased sites related to cancer, central nervous system and neurological degenerative diseases, neurodevelopmental and psychiatric disorders, and pharmaceutical preparations for the treatment of cancer, central nervous system and neurological degenerative diseases, neurodevelopmental and psychiatric disorders, for use as drug delivery vehicles that selectively targets drugs to diseased sites related to cancer, central nervous system and neurological degenerative diseases, neurodevelopmental and psychiatric disorders, with minimal side effects
01st Aug 2017
01st Aug 2017
charitable fundraising
01st Aug 2017
01st Aug 2017
No 87555042
No Service Mark
No LAUR 7323
No
No
No
No
No
No
No
No
Status Date | Action Taken |
---|---|
12th Aug 2024 | TEAS SECTION 8 & 15 RECEIVED |
28th Aug 2023 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
28th Aug 2018 | REGISTERED-PRINCIPAL REGISTER |
12th Jun 2018 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
12th Jun 2018 | PUBLISHED FOR OPPOSITION |
23rd May 2018 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
10th May 2018 | APPROVED FOR PUB - PRINCIPAL REGISTER |
08th May 2018 | TEAS/EMAIL CORRESPONDENCE ENTERED |
07th May 2018 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
07th May 2018 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |